Overview on the treatment of severe bronchial asthma
Childhood asthma, often linked with atopic conditions, poses a challenge when classified as severe and uncontrolled. The 2023 GINA guidelines define severe asthma in children as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA or requires high-dose ICS-LABA to pre...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Giulio Dinardo [verfasserIn] Cristiana Indolfi [verfasserIn] Angela Klain [verfasserIn] Chiara Lucia Bencivenga [verfasserIn] Serena Ferrara [verfasserIn] Fabio Decimo [verfasserIn] Michele Miraglia del Giudice [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2024 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Global Pediatrics ; 7(2024), Seite 100117- volume:7 ; year:2024 ; pages:100117- |
|---|
| Links: |
|---|
| DOI / URN: |
10.1016/j.gpeds.2023.100117 |
|---|
| Katalog-ID: |
DOAJ097182400 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ097182400 | ||
| 003 | DE-627 | ||
| 005 | 20240413174349.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.gpeds.2023.100117 |2 doi | |
| 035 | |a (DE-627)DOAJ097182400 | ||
| 035 | |a (DE-599)DOAJ5d948ff586e04fa68077415e1b7a4f9c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RJ1-570 | |
| 100 | 0 | |a Giulio Dinardo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Overview on the treatment of severe bronchial asthma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Childhood asthma, often linked with atopic conditions, poses a challenge when classified as severe and uncontrolled. The 2023 GINA guidelines define severe asthma in children as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA or requires high-dose ICS-LABA to prevent it from becoming uncontrolled. This category encompasses about 5% of pediatric asthma cases, emphasizing the need for innovative therapeutic exploration. Advances in understanding asthma phenotypes and endotypes enable personalized treatment based on biomarkers. Monoclonal antibodies offer targeted solutions, reducing exacerbations, improving lung function, and minimizing corticosteroid use in pediatric patients. Integrating these therapies requires a personalized approach by healthcare providers, enhancing outcomes in severe and refractory cases. | ||
| 650 | 4 | |a Asthma | |
| 650 | 4 | |a Severe asthma | |
| 650 | 4 | |a Children | |
| 650 | 4 | |a Precision medicine | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 4 | |a Biologics | |
| 653 | 0 | |a Pediatrics | |
| 700 | 0 | |a Cristiana Indolfi |e verfasserin |4 aut | |
| 700 | 0 | |a Angela Klain |e verfasserin |4 aut | |
| 700 | 0 | |a Chiara Lucia Bencivenga |e verfasserin |4 aut | |
| 700 | 0 | |a Serena Ferrara |e verfasserin |4 aut | |
| 700 | 0 | |a Fabio Decimo |e verfasserin |4 aut | |
| 700 | 0 | |a Michele Miraglia del Giudice |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Global Pediatrics |g 7(2024), Seite 100117- |
| 773 | 1 | 8 | |g volume:7 |g year:2024 |g pages:100117- |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.gpeds.2023.100117 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/5d948ff586e04fa68077415e1b7a4f9c |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S2667009723000830 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2667-0097 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2024 |h 100117- | ||
| author_variant |
g d gd c i ci a k ak c l b clb s f sf f d fd m m d g mmdg |
|---|---|
| matchkey_str |
giuliodinardocristianaindolfiangelaklain:2024----:vriwnhtetetfeeer |
| hierarchy_sort_str |
2024 |
| callnumber-subject-code |
RJ |
| publishDate |
2024 |
| allfields |
10.1016/j.gpeds.2023.100117 doi (DE-627)DOAJ097182400 (DE-599)DOAJ5d948ff586e04fa68077415e1b7a4f9c DE-627 ger DE-627 rakwb eng RJ1-570 Giulio Dinardo verfasserin aut Overview on the treatment of severe bronchial asthma 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Childhood asthma, often linked with atopic conditions, poses a challenge when classified as severe and uncontrolled. The 2023 GINA guidelines define severe asthma in children as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA or requires high-dose ICS-LABA to prevent it from becoming uncontrolled. This category encompasses about 5% of pediatric asthma cases, emphasizing the need for innovative therapeutic exploration. Advances in understanding asthma phenotypes and endotypes enable personalized treatment based on biomarkers. Monoclonal antibodies offer targeted solutions, reducing exacerbations, improving lung function, and minimizing corticosteroid use in pediatric patients. Integrating these therapies requires a personalized approach by healthcare providers, enhancing outcomes in severe and refractory cases. Asthma Severe asthma Children Precision medicine Monoclonal antibodies Biologics Pediatrics Cristiana Indolfi verfasserin aut Angela Klain verfasserin aut Chiara Lucia Bencivenga verfasserin aut Serena Ferrara verfasserin aut Fabio Decimo verfasserin aut Michele Miraglia del Giudice verfasserin aut In Global Pediatrics 7(2024), Seite 100117- volume:7 year:2024 pages:100117- https://doi.org/10.1016/j.gpeds.2023.100117 kostenfrei https://doaj.org/article/5d948ff586e04fa68077415e1b7a4f9c kostenfrei http://www.sciencedirect.com/science/article/pii/S2667009723000830 kostenfrei https://doaj.org/toc/2667-0097 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 7 2024 100117- |
| spelling |
10.1016/j.gpeds.2023.100117 doi (DE-627)DOAJ097182400 (DE-599)DOAJ5d948ff586e04fa68077415e1b7a4f9c DE-627 ger DE-627 rakwb eng RJ1-570 Giulio Dinardo verfasserin aut Overview on the treatment of severe bronchial asthma 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Childhood asthma, often linked with atopic conditions, poses a challenge when classified as severe and uncontrolled. The 2023 GINA guidelines define severe asthma in children as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA or requires high-dose ICS-LABA to prevent it from becoming uncontrolled. This category encompasses about 5% of pediatric asthma cases, emphasizing the need for innovative therapeutic exploration. Advances in understanding asthma phenotypes and endotypes enable personalized treatment based on biomarkers. Monoclonal antibodies offer targeted solutions, reducing exacerbations, improving lung function, and minimizing corticosteroid use in pediatric patients. Integrating these therapies requires a personalized approach by healthcare providers, enhancing outcomes in severe and refractory cases. Asthma Severe asthma Children Precision medicine Monoclonal antibodies Biologics Pediatrics Cristiana Indolfi verfasserin aut Angela Klain verfasserin aut Chiara Lucia Bencivenga verfasserin aut Serena Ferrara verfasserin aut Fabio Decimo verfasserin aut Michele Miraglia del Giudice verfasserin aut In Global Pediatrics 7(2024), Seite 100117- volume:7 year:2024 pages:100117- https://doi.org/10.1016/j.gpeds.2023.100117 kostenfrei https://doaj.org/article/5d948ff586e04fa68077415e1b7a4f9c kostenfrei http://www.sciencedirect.com/science/article/pii/S2667009723000830 kostenfrei https://doaj.org/toc/2667-0097 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 7 2024 100117- |
| allfields_unstemmed |
10.1016/j.gpeds.2023.100117 doi (DE-627)DOAJ097182400 (DE-599)DOAJ5d948ff586e04fa68077415e1b7a4f9c DE-627 ger DE-627 rakwb eng RJ1-570 Giulio Dinardo verfasserin aut Overview on the treatment of severe bronchial asthma 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Childhood asthma, often linked with atopic conditions, poses a challenge when classified as severe and uncontrolled. The 2023 GINA guidelines define severe asthma in children as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA or requires high-dose ICS-LABA to prevent it from becoming uncontrolled. This category encompasses about 5% of pediatric asthma cases, emphasizing the need for innovative therapeutic exploration. Advances in understanding asthma phenotypes and endotypes enable personalized treatment based on biomarkers. Monoclonal antibodies offer targeted solutions, reducing exacerbations, improving lung function, and minimizing corticosteroid use in pediatric patients. Integrating these therapies requires a personalized approach by healthcare providers, enhancing outcomes in severe and refractory cases. Asthma Severe asthma Children Precision medicine Monoclonal antibodies Biologics Pediatrics Cristiana Indolfi verfasserin aut Angela Klain verfasserin aut Chiara Lucia Bencivenga verfasserin aut Serena Ferrara verfasserin aut Fabio Decimo verfasserin aut Michele Miraglia del Giudice verfasserin aut In Global Pediatrics 7(2024), Seite 100117- volume:7 year:2024 pages:100117- https://doi.org/10.1016/j.gpeds.2023.100117 kostenfrei https://doaj.org/article/5d948ff586e04fa68077415e1b7a4f9c kostenfrei http://www.sciencedirect.com/science/article/pii/S2667009723000830 kostenfrei https://doaj.org/toc/2667-0097 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 7 2024 100117- |
| allfieldsGer |
10.1016/j.gpeds.2023.100117 doi (DE-627)DOAJ097182400 (DE-599)DOAJ5d948ff586e04fa68077415e1b7a4f9c DE-627 ger DE-627 rakwb eng RJ1-570 Giulio Dinardo verfasserin aut Overview on the treatment of severe bronchial asthma 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Childhood asthma, often linked with atopic conditions, poses a challenge when classified as severe and uncontrolled. The 2023 GINA guidelines define severe asthma in children as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA or requires high-dose ICS-LABA to prevent it from becoming uncontrolled. This category encompasses about 5% of pediatric asthma cases, emphasizing the need for innovative therapeutic exploration. Advances in understanding asthma phenotypes and endotypes enable personalized treatment based on biomarkers. Monoclonal antibodies offer targeted solutions, reducing exacerbations, improving lung function, and minimizing corticosteroid use in pediatric patients. Integrating these therapies requires a personalized approach by healthcare providers, enhancing outcomes in severe and refractory cases. Asthma Severe asthma Children Precision medicine Monoclonal antibodies Biologics Pediatrics Cristiana Indolfi verfasserin aut Angela Klain verfasserin aut Chiara Lucia Bencivenga verfasserin aut Serena Ferrara verfasserin aut Fabio Decimo verfasserin aut Michele Miraglia del Giudice verfasserin aut In Global Pediatrics 7(2024), Seite 100117- volume:7 year:2024 pages:100117- https://doi.org/10.1016/j.gpeds.2023.100117 kostenfrei https://doaj.org/article/5d948ff586e04fa68077415e1b7a4f9c kostenfrei http://www.sciencedirect.com/science/article/pii/S2667009723000830 kostenfrei https://doaj.org/toc/2667-0097 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 7 2024 100117- |
| allfieldsSound |
10.1016/j.gpeds.2023.100117 doi (DE-627)DOAJ097182400 (DE-599)DOAJ5d948ff586e04fa68077415e1b7a4f9c DE-627 ger DE-627 rakwb eng RJ1-570 Giulio Dinardo verfasserin aut Overview on the treatment of severe bronchial asthma 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Childhood asthma, often linked with atopic conditions, poses a challenge when classified as severe and uncontrolled. The 2023 GINA guidelines define severe asthma in children as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA or requires high-dose ICS-LABA to prevent it from becoming uncontrolled. This category encompasses about 5% of pediatric asthma cases, emphasizing the need for innovative therapeutic exploration. Advances in understanding asthma phenotypes and endotypes enable personalized treatment based on biomarkers. Monoclonal antibodies offer targeted solutions, reducing exacerbations, improving lung function, and minimizing corticosteroid use in pediatric patients. Integrating these therapies requires a personalized approach by healthcare providers, enhancing outcomes in severe and refractory cases. Asthma Severe asthma Children Precision medicine Monoclonal antibodies Biologics Pediatrics Cristiana Indolfi verfasserin aut Angela Klain verfasserin aut Chiara Lucia Bencivenga verfasserin aut Serena Ferrara verfasserin aut Fabio Decimo verfasserin aut Michele Miraglia del Giudice verfasserin aut In Global Pediatrics 7(2024), Seite 100117- volume:7 year:2024 pages:100117- https://doi.org/10.1016/j.gpeds.2023.100117 kostenfrei https://doaj.org/article/5d948ff586e04fa68077415e1b7a4f9c kostenfrei http://www.sciencedirect.com/science/article/pii/S2667009723000830 kostenfrei https://doaj.org/toc/2667-0097 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 7 2024 100117- |
| language |
English |
| source |
In Global Pediatrics 7(2024), Seite 100117- volume:7 year:2024 pages:100117- |
| sourceStr |
In Global Pediatrics 7(2024), Seite 100117- volume:7 year:2024 pages:100117- |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Asthma Severe asthma Children Precision medicine Monoclonal antibodies Biologics Pediatrics |
| isfreeaccess_bool |
true |
| container_title |
Global Pediatrics |
| authorswithroles_txt_mv |
Giulio Dinardo @@aut@@ Cristiana Indolfi @@aut@@ Angela Klain @@aut@@ Chiara Lucia Bencivenga @@aut@@ Serena Ferrara @@aut@@ Fabio Decimo @@aut@@ Michele Miraglia del Giudice @@aut@@ |
| publishDateDaySort_date |
2024-01-01T00:00:00Z |
| id |
DOAJ097182400 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ097182400</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413174349.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.gpeds.2023.100117</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ097182400</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5d948ff586e04fa68077415e1b7a4f9c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RJ1-570</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Giulio Dinardo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Overview on the treatment of severe bronchial asthma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Childhood asthma, often linked with atopic conditions, poses a challenge when classified as severe and uncontrolled. The 2023 GINA guidelines define severe asthma in children as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA or requires high-dose ICS-LABA to prevent it from becoming uncontrolled. This category encompasses about 5% of pediatric asthma cases, emphasizing the need for innovative therapeutic exploration. Advances in understanding asthma phenotypes and endotypes enable personalized treatment based on biomarkers. Monoclonal antibodies offer targeted solutions, reducing exacerbations, improving lung function, and minimizing corticosteroid use in pediatric patients. Integrating these therapies requires a personalized approach by healthcare providers, enhancing outcomes in severe and refractory cases.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Asthma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Severe asthma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Children</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Precision medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Monoclonal antibodies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biologics</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pediatrics</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristiana Indolfi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Angela Klain</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Lucia Bencivenga</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Serena Ferrara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabio Decimo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michele Miraglia del Giudice</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Global Pediatrics</subfield><subfield code="g">7(2024), Seite 100117-</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2024</subfield><subfield code="g">pages:100117-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.gpeds.2023.100117</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5d948ff586e04fa68077415e1b7a4f9c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S2667009723000830</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2667-0097</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2024</subfield><subfield code="h">100117-</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Giulio Dinardo |
| spellingShingle |
Giulio Dinardo misc RJ1-570 misc Asthma misc Severe asthma misc Children misc Precision medicine misc Monoclonal antibodies misc Biologics misc Pediatrics Overview on the treatment of severe bronchial asthma |
| authorStr |
Giulio Dinardo |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RJ1-570 |
| illustrated |
Not Illustrated |
| topic_title |
RJ1-570 Overview on the treatment of severe bronchial asthma Asthma Severe asthma Children Precision medicine Monoclonal antibodies Biologics |
| topic |
misc RJ1-570 misc Asthma misc Severe asthma misc Children misc Precision medicine misc Monoclonal antibodies misc Biologics misc Pediatrics |
| topic_unstemmed |
misc RJ1-570 misc Asthma misc Severe asthma misc Children misc Precision medicine misc Monoclonal antibodies misc Biologics misc Pediatrics |
| topic_browse |
misc RJ1-570 misc Asthma misc Severe asthma misc Children misc Precision medicine misc Monoclonal antibodies misc Biologics misc Pediatrics |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Global Pediatrics |
| hierarchy_top_title |
Global Pediatrics |
| isfreeaccess_txt |
true |
| title |
Overview on the treatment of severe bronchial asthma |
| ctrlnum |
(DE-627)DOAJ097182400 (DE-599)DOAJ5d948ff586e04fa68077415e1b7a4f9c |
| title_full |
Overview on the treatment of severe bronchial asthma |
| author_sort |
Giulio Dinardo |
| journal |
Global Pediatrics |
| journalStr |
Global Pediatrics |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2024 |
| contenttype_str_mv |
txt |
| container_start_page |
100117 |
| author_browse |
Giulio Dinardo Cristiana Indolfi Angela Klain Chiara Lucia Bencivenga Serena Ferrara Fabio Decimo Michele Miraglia del Giudice |
| container_volume |
7 |
| class |
RJ1-570 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Giulio Dinardo |
| doi_str_mv |
10.1016/j.gpeds.2023.100117 |
| author2-role |
verfasserin |
| title_sort |
overview on the treatment of severe bronchial asthma |
| callnumber |
RJ1-570 |
| title_auth |
Overview on the treatment of severe bronchial asthma |
| abstract |
Childhood asthma, often linked with atopic conditions, poses a challenge when classified as severe and uncontrolled. The 2023 GINA guidelines define severe asthma in children as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA or requires high-dose ICS-LABA to prevent it from becoming uncontrolled. This category encompasses about 5% of pediatric asthma cases, emphasizing the need for innovative therapeutic exploration. Advances in understanding asthma phenotypes and endotypes enable personalized treatment based on biomarkers. Monoclonal antibodies offer targeted solutions, reducing exacerbations, improving lung function, and minimizing corticosteroid use in pediatric patients. Integrating these therapies requires a personalized approach by healthcare providers, enhancing outcomes in severe and refractory cases. |
| abstractGer |
Childhood asthma, often linked with atopic conditions, poses a challenge when classified as severe and uncontrolled. The 2023 GINA guidelines define severe asthma in children as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA or requires high-dose ICS-LABA to prevent it from becoming uncontrolled. This category encompasses about 5% of pediatric asthma cases, emphasizing the need for innovative therapeutic exploration. Advances in understanding asthma phenotypes and endotypes enable personalized treatment based on biomarkers. Monoclonal antibodies offer targeted solutions, reducing exacerbations, improving lung function, and minimizing corticosteroid use in pediatric patients. Integrating these therapies requires a personalized approach by healthcare providers, enhancing outcomes in severe and refractory cases. |
| abstract_unstemmed |
Childhood asthma, often linked with atopic conditions, poses a challenge when classified as severe and uncontrolled. The 2023 GINA guidelines define severe asthma in children as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA or requires high-dose ICS-LABA to prevent it from becoming uncontrolled. This category encompasses about 5% of pediatric asthma cases, emphasizing the need for innovative therapeutic exploration. Advances in understanding asthma phenotypes and endotypes enable personalized treatment based on biomarkers. Monoclonal antibodies offer targeted solutions, reducing exacerbations, improving lung function, and minimizing corticosteroid use in pediatric patients. Integrating these therapies requires a personalized approach by healthcare providers, enhancing outcomes in severe and refractory cases. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| title_short |
Overview on the treatment of severe bronchial asthma |
| url |
https://doi.org/10.1016/j.gpeds.2023.100117 https://doaj.org/article/5d948ff586e04fa68077415e1b7a4f9c http://www.sciencedirect.com/science/article/pii/S2667009723000830 https://doaj.org/toc/2667-0097 |
| remote_bool |
true |
| author2 |
Cristiana Indolfi Angela Klain Chiara Lucia Bencivenga Serena Ferrara Fabio Decimo Michele Miraglia del Giudice |
| author2Str |
Cristiana Indolfi Angela Klain Chiara Lucia Bencivenga Serena Ferrara Fabio Decimo Michele Miraglia del Giudice |
| callnumber-subject |
RJ - Pediatrics |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1016/j.gpeds.2023.100117 |
| callnumber-a |
RJ1-570 |
| up_date |
2024-07-04T00:07:35.215Z |
| _version_ |
1803604884419772416 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ097182400</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413174349.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.gpeds.2023.100117</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ097182400</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5d948ff586e04fa68077415e1b7a4f9c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RJ1-570</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Giulio Dinardo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Overview on the treatment of severe bronchial asthma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Childhood asthma, often linked with atopic conditions, poses a challenge when classified as severe and uncontrolled. The 2023 GINA guidelines define severe asthma in children as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA or requires high-dose ICS-LABA to prevent it from becoming uncontrolled. This category encompasses about 5% of pediatric asthma cases, emphasizing the need for innovative therapeutic exploration. Advances in understanding asthma phenotypes and endotypes enable personalized treatment based on biomarkers. Monoclonal antibodies offer targeted solutions, reducing exacerbations, improving lung function, and minimizing corticosteroid use in pediatric patients. Integrating these therapies requires a personalized approach by healthcare providers, enhancing outcomes in severe and refractory cases.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Asthma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Severe asthma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Children</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Precision medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Monoclonal antibodies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biologics</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pediatrics</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristiana Indolfi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Angela Klain</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Lucia Bencivenga</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Serena Ferrara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabio Decimo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michele Miraglia del Giudice</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Global Pediatrics</subfield><subfield code="g">7(2024), Seite 100117-</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2024</subfield><subfield code="g">pages:100117-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.gpeds.2023.100117</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5d948ff586e04fa68077415e1b7a4f9c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S2667009723000830</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2667-0097</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2024</subfield><subfield code="h">100117-</subfield></datafield></record></collection>
|
| score |
7.4027834 |